ICICI Prudential Nifty Pharma Index Fund · Regular · Growth
NAV
₹19.9836
as of 30 Sept 2026
Expense Ratio
1.18%
AUM
₹122 Cr
Lumpsum returns (CAGR)
- 1Y
- +22.58%
- 3Y
- +18.99%
- 5Y
- —
- Since Inception
- +20.02%
SIP returns (XIRR)
- 1Y
- +23.41%
- 3Y
- +15.63%
- 5Y
- —
- Since Inception
- +18.37%
What history actually did — last 3 years (Oct 2023 – Sept 2026)
A ₹5,000 monthly SIP for the last 3 years (Oct 2023 – Sept 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹2,15,644 today — ₹1,75,000 invested, 14.7% XIRR.
₹1,75,000
Invested
₹2,15,644
Value today
14.7%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 3 years (Oct 2023 – Sept 2026)
Real NAV backtest
₹1,00,000 invested 3 years ago would be ₹1,70,070 today (19.4% CAGR).
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 3 years (Oct 2023 – Sept 2026) (3 Jun 2024) would be ₹1,38,784 today (1.39×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised0.98
Sharpe Ratio
—
Alpha
—
Beta
1.00
Sortino
13.99%
Std Dev
-7.53%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Aug 2026Each sector links to the mutual funds most exposed to it.
Thinking about ICICI Prudential Nifty Pharma Index Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
What this fund does
ICICI Prudential Nifty Pharma Index Fund · Regular · Growth is a passively managed fund that tracks a specific market index, aiming to replicate its returns with minimal tracking error. Index funds offer low-cost, diversified exposure to the market with full transparency of holdings.
About This Fund
ICICI Prudential Nifty Pharma Index Fund · Regular · Growth is a Index Fund mutual fund offered by ICICI Prudential Mutual Fund. The fund has been operational for over 3 years. It manages assets worth ₹122 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against Nifty Pharma TRI. The current expense ratio is 1.18%.
Who Should Invest?
- •Cost-conscious investors who prefer passive investing with low expense ratios